ANGLE PLC (LON:AGL OTCQX:ANPCY) said Queen Mary University of London has been awarded a European patent over a new and potentially ground-breaking method of cancer prognosis that uses the company’s liquid biopsy.
The AIM-listed med-tech firm has an option to take ownership of the procedure that is in place until June 2021 that allows it to expand the array of tests offered by its Parsortix device.
Queen Mary’s approach was to use the ANGLE technology to process blood so megakaryocyte cells could be counted.
There was a strong correlation between the number of these large bone marrow cells and patient survival, researchers found when assessing prostate cancer sufferers.
“We welcome the acceptance of this European patent and are excited by the potential for this entirely new way of assessing cancer through a simple blood test that has been enabled by ANGLE’s Parsortix system,” said chief executive Andrew Newland.
“We will now be investigating the possibility of adding megakaryocyte tests to our existing CTC [circulating tumour] tests as part of our sample-to-answer imaging solution under development.”
Parsortix is currently the only automated system that has demonstrated the capability of harvesting megakaryocytes.
The company said patents in other countries are being sought for the new method of assessing for cancer.